Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (epididymal efferent duct ciliated cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: ni-0801, eldelumab | 0.81 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 35 Parkinson's papers of 9,548 | 0.53 |
| pathways Reactome | 3 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 3229
Sealed predictions
- CXCL10 in dopamine neurons, braak+0.75 (p 0.019) → -0.53 (p 0.146)receipt 3235
Swarm cases
receipt 3235: CXCL10 in dopamine neurons, braak
- power
- full sample -0.04 (p 0.881, n 18), 95% CI -0.50 to +0.44. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.03 (p 0.901, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.29 (p 0.243, n 18). could be the mix.
- skeptic
- leave-one-out range -0.16 to +0.08, sign flips 5; without severely affected donors -0.04 (p 0.881, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CXCL10 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts